References

Update on the epidemiology of carbapenemases in Latin America and the Caribbean

10.1080/14787210.2020.1813023 · 2021 · External reference

A Seven-Year Microbiological and Molecular Study of Bacteremias Due to Carbapenemase-Producing Klebsiella pneumoniae: An Interrupted Time-Series Analysis of Changes in the Carbapenemase Gene’s Distribution after Introduction of Ceftazidime/Avibactam

10.3390/antibiotics11101414 · 2022 · External reference

Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam

10.1093/jac/dkz125 · 2019 · External reference

Healthcare-associated carbapenem-resistant Klebsiella pneumoniae bloodstream infections: Risk factors, mortality, and antimicrobial susceptibility, 2017–2019

10.1016/j.jfma.2021.04.014 · 2021 · External reference

Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae

10.1128/aac.02373-13 · 2014 · External reference

Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes

10.1016/j.diagmicrobio.2010.02.001 · 2010 · External reference

Risks of Infection and Mortality Among Patients Colonized with Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae: Validation of Scores and Proposal for Management

10.1093/cid/cix991 · 2018 · External reference

Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales

10.1128/aac.01676-21 · 2022 · External reference

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

10.1016/j.cmi.2021.11.025 · 2022 · External reference

Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment

10.1111/j.1469-0691.2011.03514.x · 2011 · External reference

Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: Can we apply “precision medicine” to antimicrobial chemotherapy?

10.1517/14656566.2016.1145658 · 2016 · External reference

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients

10.1016/j.ijid.2017.03.021 · 2017 · External reference

Change in Klebsiella pneumoniae susceptibility profile after the arrival of ceftazidime-avibactam in an Argentinean intensive care unit: a new ecological landscape

10.37201/req/042.2024 · 2024 · External reference

Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study

10.1111/1469-0691.12747 · 2014 · External reference

Evaluación del Gianella Risk Score en pacientes adultos con colonización rectal por Klebsiella pneumoniae productora de carbapenemasas en el Hospital General del Norte de Guayaquil Los Ceibos, durante el periodo de enero 2018 a junio 2019

10.46721/tejom-vol3iss1-2021-30-45 · 2021 · External reference

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

10.1016/s1473-3099(17)30228-1 · 2017 · External reference

Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: Who is prone to become clinically infected?

10.1111/j.1469-0691.2012.03888.x · 2013 · External reference

Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae

10.1016/j.ajic.2011.05.022 · 2012 · External reference

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

10.1093/cid/cis588 · 2012 · External reference

Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections

10.1111/j.1469-0691.2011.03478.x · 2012 · External reference

Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems

10.1128/aac.00406-17 · 2017 · External reference

A Predictive Model of Mortality in Patients with Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

10.1016/j.mayocp.2016.06.024 · 2016 · External reference

The Global Burden of Sepsis and Septic Shock

10.3390/epidemiologia5030032 · 2024 · External reference

Unresolved reference

2017 · External reference

Klebsiella pneumoniae Carbapenemase–2, Buenos Aires, Argentina

10.3201/eid1407.070826 · 2008 · External reference

Unresolved reference

2019 · External reference

The post-antibiotic era has arrived: interventions to contain an outbreak of pan-drug-resistant (PDR) NDM-1 and OXA-48-like dual-producer Providencia stuartii in an acute care hospital in Argentina

2017 · External reference

Emergence of NDM-1-producing Klebsiella pneumoniae in Guatemala

10.1093/jac/dks101 · 2012 · External reference

Evaluation of the Blue-Carba Test for Rapid Detection of Carbapenemases in Gram-Negative Bacilli

10.1128/jcm.03026-14 · 2015 · External reference

Unresolved reference

2019 · External reference